2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4264 Scheduled low-dose rituximab prophylaxis reduces post-transplant EBV dnaemia in allogeneic hematopoietic stem cell transplantation: A single-center retrospective cohort study

Xiaomeng Feng Jr, sisi zhen2, Yigeng Cao II, MD, PhD3, Sizhou Feng4, Donglin Yang5, Erlie Jiang, MD6
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background

Epstein–Barr virus (EBV) DNAemia remains a clinically important complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in recipients exposed to intensive immunosuppression, antithymocyte globulin (ATG), or HLA-mismatched transplantation. EBV DNAemia may precede EBV-associated post-transplant lymphoproliferative disorder (PTLD), and serial EBV monitoring followed by preemptive rituximab is widely used. However, whether scheduled prophylactic anti-CD20 therapy can reduce EBV DNAemia before viral reactivation occurs remains uncertain. 

Methods

We retrospectively analyzed 489 consecutive patients undergoing allo-HSCT at a single center. Patients were categorized according to receipt of prophylactic rituximab: no prophylaxis (n=393) and rituximab prophylaxis (n=96). In the prophylaxis group, rituximab 100 mg was administered intravenously on days +21 and +28 after transplantation.

Plasma EBV-DNA and CMV-DNA levels were monitored by quantitative PCR according to institutional surveillance protocol after transplantation. Patients who developed EBV DNAemia received preemptive treatment according to institutional practice. The primary endpoint was cumulative incidence of EBV DNAemia, with death before EBV DNAemia treated as a competing event. Cumulative incidence functions were compared using Gray’s test. Fine–Gray competing-risk regression was used to estimate subdistribution hazard ratios (sHRs) for EBV DNAemia. Secondary endpoints included cumulative incidence of CMV DNAemia, bacteremia, and OS. CMV DNAemia was analyzed using competing-risk methods, bacteremia was compared using logistic regression, and OS was estimated by Kaplan–Meier analysis and compared using the log-rank test. Multivariable models adjusted for age, disease status at transplantation, donor type, and ATG-containing conditioning.

Results
The median follow-up was 272 days. The median age was 40.4 years, 60.5% of patients had acute leukemia, 72.0% underwent haploidentical transplantation, and 82.4% received ATG-containing conditioning. Baseline clinical and transplant characteristics were generally balanced between groups, except for donor type distribution, which was adjusted for in multivariable analyses.

Overall, EBV DNAemia occurred in 83 patients (17.0%). EBV DNAemia developed in 79/393 (20.1%) patients in the no prophylaxis group and 4/96 (4.2%) patients in the rituximab prophylaxis group. The cumulative incidence of EBV DNAemia was significantly lower in the rituximab prophylaxis group than in the no prophylaxis group at day 100 (4.2% vs 19.4%), day 180 (4.2% vs 19.6%), and day 365 (4.2% vs 20.3%) after allo-HSCT (Gray’s test, *P*<0.001).

In univariable Fine–Gray regression, rituximab prophylaxis was associated with a significantly lower risk of EBV DNAemia (sHR, 0.19; 95% CI, 0.07–0.51; *P*=0.001). After adjustment for prespecified clinical and transplant-related covariates, rituximab prophylaxis remained independently associated with reduced EBV DNAemia (adjusted sHR, 0.18; 95% CI, 0.06–0.48; *P*<0.001).

The 365-day cumulative incidence of CMV DNAemia was similar between the rituximab prophylaxis and no prophylaxis groups (17.1% vs 20.4%, Gray’s test, *P*=0.55). Bacteremia occurred in 13/96 (13.5%) patients receiving rituximab prophylaxis and 102/393 (26.0%) patients without prophylaxis. No prophylaxis was associated with higher odds of bacteremia compared with rituximab prophylaxis (odds ratio, 2.24; 95% CI, 1.23–4.36; *P*=0.01). OS did not differ significantly between groups (log-rank *P*=1.00), with 365-day OS rates of 88.6% versus 89.1%.

Conclusions
In this single-center retrospective cohort, scheduled low-dose rituximab prophylaxis administered on days +21 and +28 after allo-HSCT was independently associated with a marked reduction in EBV DNAemia. This strategy was not associated with increased CMV DNAemia and was associated with a lower observed incidence of bacteremia, while OS remained comparable between groups. These findings support early post-transplant CD20-directed prophylaxis as a potentially effective EBV prevention strategy in allo-HSCT recipients, particularly in settings with intensive EBV surveillance and high proportions of ATG exposure or haploidentical transplantation. Prospective validation is underway in a randomized controlled trial (NCT07703657).

 

Xiaomeng Feng Jr: No relevant conflicts of interest to declare.